Malignant diseases (hematological and onocological) linked to BRAF or other RAF (RAF1, ARAF) mutations
Conditions
Interventions
Group 1: Patients with diagnosis of a cancer with an alteration in BRAF or related genes (ARAF, RAF1) referred to the molecular tumorboard at any of the participating ZPM sites, irrespective of cancer
Sponsors
Universitätsklinikum Freiburg, Klinik für Innere Medizin 1
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: o Diagnosis of a cancer with an alteration in BRAF or related genes referred to the MTBs at any of the above mentioned ZPM site, irrespective of cancer entity. o Patient’s written consent is available.
Exclusion criteria
Exclusion criteria: - Denial or withdrawal of written consent. - mutation which cannot be linked to any manifestation of malignancy as judged from a bioinformatical and molecular medicine perspective
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival after standard of care treatment and personalized treatment recommendations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival after standard of care treatment and personalized treatment recommendations. | — |
Countries
Germany
Contacts
Public ContactKhalid Shoumariyeh
Universitätsklinikum Freiburg, Klinik für Innere Medizin 1
Outcome results
None listed